Comprehensive reviews of the literature related to management and diagnosis of pheochromocytoma are available elsewhere.
The pheochromocytoma-like symptoms resolved completely following surgery. The final diagnosis was pheochromocytoma syndrome (that is, symptoms of pheochromocytoma secondary to adrenal pathology ...
Low-osmolar, contrast-enhanced CT can be safely used in patients with pheochromocytoma. “This tool will enhance physicians' abilities to diagnose and treat patients with pheochromocytoma ...
Spear and Griswald 9 reported the first case of a fall in blood pressure after the administration of dibenamine (N, N-dibenzyl-β-chloroethylamine) to a patient who proved at operation to have a ...
The diagnosis of idiopathic intracranial hypertension readily prevails upon detection of optic disc edema associated with headache despite having well-established diagnostic criteria. [2] Without ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...
In a series by Petr and Else, mean age at diagnosis in this patient group ... This justifies ruling out pheochromocytoma in NF1 patients before elective surgeries under general anesthetic, as ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback